It is used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
Antiasthmatic & COPD Preparations
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Allergic rhinitis, Asthma
Adult: 225 mg bid.
Child: 3.5 mg/kg bid. Max dose: 10 mg/kg/day (not exceeding 450 mg daily).
Concurrent use with warfarin and other anticoagulants may cause an increase in prothrombin time.
Acute asthma attacks; hepatic impairment/cirrhosis.
Headache, increased incidence of resp tract infection, GI disturbances, induced generalised pain, fever, myalgia, arthralgia.
Use of pranlukast is not associated with an increased risk of pregnancy loss, gestational diabetes, preeclampsia, low maternal weight, preterm delivery, low apgar scores and reduced measures of birth length in infants. Slightly decreased birth weight in infants born to pranlukast users could be attributed to maternal asthma severity/control.
Store at room temperature below 30°C.
.png&w=384&q=75)